期刊
STEM CELLS
卷 33, 期 4, 页码 1200-1212出版社
WILEY
DOI: 10.1002/stem.1934
关键词
Mesenchymal stromal cells; T cells; x-GVHD; Adenosine
资金
- Intramural Research Program, Center for Cancer Research, National Cancer Institute
- DIR, National Institute of Dental and Craniofacial Research
- NIH Clinical Center
- NIH Bone Marrow Stromal Cell Transplantation Center
- National Heart, Lung and Blood Institute, National Institutes of Health
The use of bone marrow-derived mesenchymal stromal cells (BMSC) in the treatment of alloimmune and autoimmune conditions has generated much interest, yet an understanding of the therapeutic mechanism remains elusive. We therefore explored immune modulation by a clinical-grade BMSC product in a model of human-into-mouse xenogeneic graft-versus-host disease (x-GVHD) mediated by human CD4(+) Th1 cells. BMSC reversed established, lethal x-GVHD through marked inhibition of Th1 cell effector function. Gene marking studies indicated BMSC engraftment was limited to the lung; furthermore, there was no increase in regulatory T cells, thereby suggesting a paracrine mechanism of BMSC action. BMSC recipients had increased serum CD73 expressing exosomes that promoted adenosine accumulation ex vivo. Importantly, immune modulation mediated by BMSC was fully abrogated by pharmacologic therapy with an adenosine A2A receptor antagonist. To investigate the potential clinical relevance of these mechanistic findings, patient serum samples collected pre- and post-BMSC treatment were studied for exosome content: CD73 expressing exosomes promoting adenosine accumulation were detected in post-BMSC samples. In conclusion, BMSC effectively modulate experimental GVHD through a paracrine mechanism that promotes adenosine-based immune suppression. Stem Cells 2015;33:1200-1212 Stem Cells2015;33:1200-1212
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据